SNTI (Senti Biosciences Holdings) ROA %: -37.74% (As of Mar. 2026)


SNTI Senti Biosciences Holdings Inc SNTI
22 GF Score
Price $1.03
! 7 Warning Signs
View Full Analysis

What is Senti Biosciences Holdings ROA %?

Senti Biosciences Holdings SNTI +3.00% 22 ROA % is -37.74% as of Mar. 2026. GuruFocus rates SNTI with a GF Score™ of 22/100. The stock has 7 warning signs investors should review. Among 1,416 Biotechnology companies, Senti Biosciences Holdings ranks worse than 79.8% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Senti Biosciences Holdings's annualized Net Income for the quarter that ended in Mar. 2026 was $-16.88 Mil. Senti Biosciences Holdings's average Total Assets over the quarter that ended in Mar. 2026 was $44.73 Mil. Therefore, Senti Biosciences Holdings's annualized ROA % for the quarter that ended in Mar. 2026 was -37.74%.

The historical rank and industry rank for Senti Biosciences Holdings's ROA % or its related term are showing as below:

SNTI' s ROA % Range Over the Past 10 Years
Min: -87.82   Med: -47.96   Max: -41.08
Current: -87.82

During the past 6 years, Senti Biosciences Holdings's highest ROA % was -41.08%. The lowest was -87.82%. And the median was -47.96%.

SNTI's ROA % is ranked worse than
79.8% of 1416 companies
in the Biotechnology industry
Industry Median: -32.87 vs SNTI: -87.82

Senti Biosciences Holdings  (NAS:SNTI) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-16.884/44.732
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-16.884 / 0.064)*(0.064 / 44.732)
=Net Margin %*Asset Turnover
=-26381.25 %*0.0014
=-37.74 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Senti Biosciences Holdings ROA % Related Terms


Senti Biosciences Holdings ROA % Historical Data

* Premium members only.

The historical data trend for Senti Biosciences Holdings's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senti Biosciences Holdings ROA % Chart

Senti Biosciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
Get a 7-Day Free Trial -76.28 -41.95 -47.33 -48.58 -82.43

Senti Biosciences Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.51 -77.89 -119.62 -111.38 -37.74

SNTI vs ALGS, CRVO, NTRB: ROA % Comparison

For the Biotechnology subindustry, Senti Biosciences Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senti Biosciences Holdings ROA % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's ROA % distribution charts can be found below:

* The bar in red indicates where Senti Biosciences Holdings's ROA % falls into.


SNTI
22GF Score
Senti Biosciences Holdings Inc SNTI
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senti Biosciences Holdings ROA % Calculation

Senti Biosciences Holdings's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-61.438/( (97.841+51.223)/ 2 )
=-61.438/74.532
=-82.43 %

Senti Biosciences Holdings's annualized ROA % for the quarter that ended in Mar. 2026 is calculated as:

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-16.884/( (51.223+38.241)/ 2 )
=-16.884/44.732
=-37.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -37.74% mean?
Senti Biosciences Holdings (SNTI) has a ROA % of -37.74% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Senti Biosciences Holdings and its competitors. According to the industry distribution chart, Senti Biosciences Holdings ranks #1130 out of 1416 companies in the Biotechnology industry, placing it in the top 79.8%.
Is Senti Biosciences Holdings' ROA % too high?
Senti Biosciences Holdings' current ROA % is -37.74%. Based on the distribution chart, Senti Biosciences Holdings ranks #1130 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Senti Biosciences Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' ROA % compare to ALGS and CRVO?
According to the Biotechnology industry distribution chart, Senti Biosciences Holdings ranks #1130 out of 1416 companies for ROA %. This places Senti Biosciences Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Senti Biosciences Holdings and its competitors. Senti Biosciences Holdings's current ROA % is -37.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current ROA % of -37.74%. The current ROA % is -37.74%. Senti Biosciences Holdings' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current ROA % is -37.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senti Biosciences Holdings Business Description

Address 2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
22GF Score

Get the complete analysis for SNTI

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price